{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:12:23Z","timestamp":1696061543494},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The sulfone dapsone has an established role in systemic therapy. Its pharmacological and toxicological properties are well known. Topically, dapsone is used in a gel formulation for the treatment of acne vulgaris. In addition, there have been individual case reports on the efficacy of topical dapsone preparations in the treatment of various neutrophilic dermatoses. To date, no finished medicinal product for topical use has been available in Germany.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>Against this background, we set out to develop extemporaneous preparations containing dapsone (5\u00a0%) that meet the quality requirements of the European Pharmacopoeia as well as the manufacturing requirements of the German Ordinance on the Operation of Pharmacies (ApBetrO). These formulations included the incorporation of dapsone in a hydrophobic cream base (\u201chydrophobe Basiscreme DAC\u201d) as well as in methylprednisolone aceponate 0.1\u00a0% ointment (alternatively, in the latter's cream base without active ingredient).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Tests aimed at investigating the physical, chemical, and microbiological stability of these formulations showed them to meet the aforementioned quality requirements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The extemporaneous formulations presented herein broaden the therapeutic options for topical treatment, in particular for patients with chronic inflammatory dermatoses associated with a neutrophilic pathogenesis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.13409","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T13:14:55Z","timestamp":1514380495000},"page":"34-40","source":"Crossref","is-referenced-by-count":0,"title":["Dapsone for topical use in extemporaneous preparations"],"prefix":"10.1111","volume":"16","author":[{"given":"Johannes","family":"Wohlrab","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"},{"name":"Institute for Applied Dermatopharmacy Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Michael","sequence":"additional","affiliation":[{"name":"Institute for Applied Dermatopharmacy Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"WozelG.Dapson \u2013 Pharmakologie Wirkmechanismus und klinischer Einsatz. G. Thieme Verlag Stuttgart New York 1996."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746080-00006"},{"key":"e_1_2_8_4_1","first-page":"171","article-title":"Efficacy and safety of dapsone gel 5 % for the treatment of acne vulgaris in adolescents","volume":"81","author":"Raimer S","year":"2008","journal-title":"Cutis"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.518"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-3186","article-title":"Case report of methemoglobinemia in a toddler secondary to topical dapsone exposure","volume":"138","author":"Graff DM","year":"2016","journal-title":"Pediatrics"},{"key":"e_1_2_8_7_1","first-page":"492","article-title":"Methemoglobinemia as a complication of topical dapsone","volume":"372","author":"Watton C","year":"2015","journal-title":"N Engl J Med"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1408272"},{"key":"e_1_2_8_9_1","first-page":"553","article-title":"Efficacy and safety of once\u2010daily dapsone gel, 7.5 % for treatment of adolescents and adults with acne vulgaris: first of two identically designed, large, multicenter, randomized, vehicle\u2010controlled trials","volume":"15","author":"Stein Gold LF","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_10_1","first-page":"1417","article-title":"The efficacy and tolerability of dapsone 5 % gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable","volume":"11","author":"Tanghetti E","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200910040-00002"},{"key":"e_1_2_8_12_1","first-page":"981","article-title":"Dapsone gel 5 % for the treatment of acne vulgaris: safety and efficacy of long\u2010term (1 year) treatment","volume":"6","author":"Lucky AW","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_13_1","first-page":"602","article-title":"Dapsone gel in the treatment of papulopustular rosacea: a double\u2010blind randomized clinical trial","volume":"14","author":"Faghihi G","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/1203475416651053","article-title":"Topical dapsone 5 % gel as an effective therapy in dermatitis herpetiformis","volume":"20","author":"Burbidge T","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"e_1_2_8_15_1","first-page":"481","article-title":"Novel use of topical dapsone 5 % gel for erythema elevatum diutinum: safer and effective","volume":"12","author":"Frieling GW","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_16_1","first-page":"48","article-title":"Management of periocular granuloma annulare using topical dapsone","volume":"8","author":"Kassardjian M","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","DOI":"10.5070\/D3208023535","article-title":"Granuloma faciale treated with topical dapsone: a case report","volume":"20","author":"Babalola O","year":"2014","journal-title":"Dermatol Online J"},{"key":"e_1_2_8_18_1","first-page":"1059","article-title":"Treatment of peristomal pyoderma gangrenosum with topical crushed dapsone","volume":"10","author":"Handler MZ","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-013-1409-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2131\/jts.38.215"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/ddg.13151","article-title":"Topical preparations and their use in dermatology","volume":"14","author":"Wohlrab J.","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/ddg.12622","article-title":"Methotrexate for topical application in an extemporaneous preparation","volume":"13","author":"Wohlrab J","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_8_23_1","unstructured":"Commitee for Medicinal Products for Human Use (CHMP).Guideline on bioanalytical method validation.2011. Available from:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf[Last accessed May 5 2017]."},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)84117-1"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1345\/aph.19273","article-title":"Stability of dapsone in two oral liquid dosage forms","volume":"34","author":"Nahata MC","year":"2000","journal-title":"Ann Pharmacother"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:29:35Z","timestamp":1695972575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/ddg.13409"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13409","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}